Frank C Cackowski
Overview
Explore the profile of Frank C Cackowski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
760
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Cackowski F, Korkaya H
Cancer Res
. 2024 Oct;
84(20):3319-3321.
PMID: 39402990
Many solid tumors including breast cancer can exhibit early dissemination and dormancy-in which cancer cells spread early in the disease process and survive long periods without detectable growth. These early...
2.
Brown M, DAnniballe V, Boczkowski D, Kandadi H, Sheikh N, Kornahrens Jr W, et al.
Cancer Res Commun
. 2024 Sep;
4(10):2724-2733.
PMID: 39320053
Significance: The identification of factors that determine successful cancer immunotherapy, particularly in refractory tumor types like mCRPC, is urgently needed: both to identify patients that may benefit from such therapies...
3.
Heath E, Dyson G, Ribeiro J, Xiu J, Poorman K, Mamdani H, et al.
Cancer Res Commun
. 2024 Aug;
4(10):2598-2609.
PMID: 39172022
Health disparities present a barrier to successful oncology treatment. The potential for precision oncology to reduce health disparities has not previously been analyzed. We performed a retrospective analysis of 12,627...
4.
Heath E, Thakur A, Chen W, Hwang C, Paller C, Cackowski F, et al.
Cancer Res Commun
. 2024 Jun;
4(7):1715-1725.
PMID: 38856749
Significance: Our novel findings of higher expression of co-stimulatory receptor ICOS on CD4+ and CD8+ T cells in African American patients with metastatic castrate-resistant prostate cancer (mCRPC) prior and post-sipuleucel-T...
5.
Church S, Pulianmackal A, Dixon J, Loftus L, Amend S, Pienta K, et al.
bioRxiv
. 2024 Jun;
PMID: 38853988
models for tumorigenesis and metastasis have revealed conserved mechanisms of signaling that are also involved in mammalian cancer. Many of these models use the proliferating tissues of the larval stages...
6.
Park J, Chu A, Li J, Ali A, McKay R, Hwang C, et al.
JCO Precis Oncol
. 2024 Apr;
8:e2300567.
PMID: 38579192
Purpose: There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) testing in the...
7.
Hwang C, Henderson N, Chu S, Holland B, Cackowski F, Pilling A, et al.
JAMA Netw Open
. 2023 Sep;
6(9):e2334208.
PMID: 37721753
Importance: Black men have higher incidence and mortality from prostate cancer. Whether precision oncology disparities affect Black men with metastatic castration-resistant prostate cancer (mCRPC) is unknown. Objective: To compare precision...
8.
Zielske S, Chen W, Ibrahim K, Cackowski F
BMC Cancer
. 2023 Jul;
23(1):672.
PMID: 37464317
Background: A majority of prostate cancer cells are in a non-proliferating, G (quiescent) phase of the cell cycle and may lie dormant for years before activation into a proliferative, rapidly...
9.
Yumoto K, Rashid J, Ibrahim K, Zielske S, Wang Y, Omi M, et al.
Transl Oncol
. 2023 Feb;
31:101642.
PMID: 36805918
Quiescent prostate cancer (PCa) cells are common in tumors but are often resistant to chemotherapy. Quiescent PCa cells are also enriched for a stem-like tumor initiating population, and can lead...
10.
Zielske S, Cackowski F
Funct Integr Genomics
. 2022 Dec;
23(1):2.
PMID: 36526938
No abstract available.